Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve a lawsuit claiming they defrauded ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published ...

Healthcare giant Pfizer ( PFE 2.24%) has been offering a high yield for some time. But that hasn't been enough to get ...

Pfizer and manufacturer Tris Pharma have agreed to hand over $41.5 million to lay to rest a 2023 lawsuit accusing the ...

Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Texas Attorney General Paxton secures a $41.5 million settlement with Pfizer and Tris Pharma over allegations of providing ...

Pfizer has won a $10 billion deal to acquire obesity drug developer Metsera, securing foothold in lucrative weight-loss ...

Pfizer and Tris Pharma will pay $41.5 million to settle allegations they provided an ADHD medicine knowing about “flawed” manufacturing practices ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...

Discover why Pfizer stock may be set for a bull run by 2026 with key wins, strong Q3 earnings, and growth drivers.

Pfizer eventually increased its offer. The company is now set to acquire Metsera in a deal worth up to $10 billion, including ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...